NASDAQ:ALNY
$188.26
(
1.22%
)
Friday, 26th May 2023
Alnylam Pharmaceuticals Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $183.00 | $212.47 | Friday, 26th May 2023 ALNY stock ended at $188.26. This is 1.22% more than the trading day before Thursday, 25th May 2023. During the day the stock fluctuated 2.02% from a day low at $185.13 to a day high of $188.87. |
| 90 days | $179.19 | $212.47 | |
| 52 weeks | $120.43 | $242.97 |
Historical Alnylam Pharmaceuticals prices
| Date | Open | High | Low | Close | Volume |
| 2023-05-26 | $188.33 | $188.87 | $185.13 | $188.26 | 421 982 |
| 2023-05-25 | $185.93 | $186.47 | $183.00 | $186.00 | 506 085 |
| 2023-05-24 | $191.12 | $192.07 | $185.63 | $185.92 | 542 977 |
| 2023-05-23 | $193.06 | $194.68 | $190.68 | $191.83 | 388 341 |
| 2023-05-22 | $191.38 | $194.01 | $189.30 | $193.06 | 570 737 |
| 2023-05-19 | $191.48 | $193.49 | $189.58 | $190.74 | 289 506 |
| 2023-05-18 | $191.10 | $191.60 | $186.26 | $189.87 | 422 175 |
| 2023-05-17 | $191.28 | $193.75 | $187.17 | $193.23 | 485 590 |
| 2023-05-16 | $202.70 | $202.70 | $189.21 | $190.97 | 1 269 862 |
| 2023-05-15 | $205.66 | $208.11 | $204.36 | $206.20 | 367 900 |
| 2023-05-12 | $206.11 | $208.13 | $204.46 | $205.36 | 314 329 |
| 2023-05-11 | $211.16 | $211.16 | $204.15 | $206.09 | 292 975 |
| 2023-05-10 | $209.39 | $211.85 | $208.40 | $210.97 | 532 540 |
| 2023-05-09 | $207.81 | $209.57 | $204.43 | $207.83 | 501 668 |
| 2023-05-08 | $211.34 | $211.35 | $205.66 | $209.96 | 542 921 |
| 2023-05-05 | $209.01 | $212.47 | $207.17 | $212.05 | 655 371 |
| 2023-05-04 | $201.72 | $206.36 | $200.04 | $205.39 | 776 356 |
| 2023-05-03 | $200.70 | $203.10 | $198.21 | $199.50 | 690 685 |
| 2023-05-02 | $201.37 | $203.16 | $198.42 | $199.02 | 571 837 |
| 2023-05-01 | $198.87 | $202.84 | $196.73 | $201.87 | 605 815 |
| 2023-04-28 | $195.13 | $201.42 | $193.96 | $199.20 | 591 057 |
| 2023-04-27 | $197.08 | $197.27 | $192.38 | $196.04 | 938 765 |
| 2023-04-26 | $200.61 | $201.28 | $195.94 | $197.52 | 435 562 |
| 2023-04-25 | $204.89 | $205.46 | $199.55 | $202.15 | 436 026 |
| 2023-04-24 | $209.12 | $209.51 | $203.81 | $204.79 | 443 266 |
| 2023-04-21 | $204.73 | $209.79 | $203.77 | $209.28 | 746 865 |
| 2023-04-20 | $199.82 | $203.53 | $199.61 | $202.86 | 840 171 |
| 2023-04-19 | $201.22 | $204.86 | $201.22 | $202.30 | 1 318 606 |
| 2023-04-18 | $207.29 | $208.00 | $200.19 | $201.67 | 972 936 |
| 2023-04-17 | $205.29 | $206.56 | $202.91 | $205.91 | 474 383 |
| 2023-04-14 | $206.44 | $208.77 | $202.30 | $203.92 | 686 761 |
| 2023-04-13 | $204.18 | $209.29 | $204.11 | $207.33 | 1 432 491 |
| 2023-04-12 | $205.00 | $206.70 | $202.23 | $202.89 | 705 129 |
| 2023-04-11 | $205.44 | $207.96 | $202.23 | $202.81 | 687 113 |
| 2023-04-10 | $209.74 | $209.74 | $201.47 | $205.44 | 663 517 |
| 2023-04-06 | $200.40 | $211.27 | $199.52 | $210.99 | 1 194 726 |
| 2023-04-05 | $202.34 | $204.80 | $200.35 | $200.82 | 615 585 |
| 2023-04-04 | $201.09 | $202.81 | $198.89 | $202.70 | 435 011 |
| 2023-04-03 | $198.60 | $203.12 | $197.78 | $200.70 | 837 858 |
| 2023-03-31 | $195.50 | $200.87 | $195.50 | $200.32 | 1 155 980 |
| 2023-03-30 | $196.47 | $197.92 | $190.85 | $195.12 | 587 473 |
| 2023-03-29 | $188.61 | $196.23 | $188.14 | $195.91 | 806 829 |
| 2023-03-28 | $190.51 | $194.25 | $187.94 | $188.55 | 1 304 918 |
| 2023-03-27 | $191.02 | $191.81 | $188.00 | $190.51 | 938 366 |
| 2023-03-24 | $190.25 | $190.40 | $185.89 | $189.98 | 351 463 |
| 2023-03-23 | $192.54 | $195.16 | $189.11 | $190.49 | 458 536 |
| 2023-03-22 | $190.46 | $194.76 | $187.40 | $189.74 | 1 237 136 |
| 2023-03-21 | $189.35 | $191.06 | $187.81 | $190.43 | 958 575 |
| 2023-03-20 | $185.07 | $188.25 | $182.30 | $187.52 | 560 163 |
| 2023-03-17 | $187.30 | $189.14 | $184.07 | $185.45 | 883 353 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f... ALNY Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
